Baird Starts Coherus Biosciences (CHRS) at Outperform

October 18, 2016 4:05 PM EDT
Get Alerts CHRS Hot Sheet
Price: $27.90 +1.27%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade CHRS Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Baird initiates coverage on Coherus Biosciences (NASDAQ: CHRS) with a Outperform rating and a price target of $40.00.

Analyst Michael Ulz commented, "We view Coherus as a potential leader in the biosimilar space with an experienced management team and differentiated legal strategy. Coherus boasts a robust late-stage biosimilar pipeline, including CHS-1701 (Neulasta biosimilar) under regulatory review, CHS-1420 (Humira biosimilar) in Phase 3, and CHS-0214 (Enbrel biosimilar) filing early next year in Europe. We expect numerous meaningful catalysts ahead to drive further upside, culminating in the launch of its first biosimilar product in 2018."

For an analyst ratings summary and ratings history on Coherus Biosciences click here. For more ratings news on Coherus Biosciences click here.

Shares of Coherus Biosciences closed at $28.88 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird, S1

Add Your Comment